Advertisement News Archives - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

News

April 3, 2020

Vir and Alnylam expand collaboration to advance investigational RNAi therapeutics targeting host factors for treatment of COVID-19

Vir Biotechnology and Alnylam Pharmaceuticals, Inc. announced an expansion to their broad multi-target existing collaboration for the development and commercialization of RNAi therapeutics for infectious diseases, including SARS-CoV-2, the virus that causes the disease COVID-19.

Vir and Alnylam expand collaboration to advance investigational RNAi therapeutics targeting host factors for treatment of COVID-19